ischemic cardiomyopathy
Conditions
Interventions
Exposure Group (Shexiang Baoxin Pill plus standardized anti-heart failure therapy) :None
Non-exposure Group (standardized anti-heart failure therapy):None
Sponsors
The Second Affiliated Hospital of Hainan Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years, with no gender restriction; 2. Diagnosed with significant stenosis (>= 75%) in at least one coronary artery by coronary angiography or coronary CTA, or with a history of Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG), and receiving secondary prevention therapy for coronary heart disease; 3. Presence of heart failure symptoms or signs such as chest tightness, dyspnea, or edema, with NT-proBNP > 125ng/L; 4. New York Heart Association (NYHA) functional class II–IV; 5. Patients voluntarily sign the informed consent form for this study.
Exclusion criteria
Exclusion criteria: 1. Patients with malignant hypertension; 2. Patients with severe arrhythmia, valvular heart disease, or cardiogenic shock; 3. Patients with moderate to severe hepatic or renal dysfunction, complicated by severe metabolic diseases, hematological diseases, or malignant tumors; 4. Patients with excessive missing medical records and biochemical index data; 5. Pregnant women, lactating women, or women of childbearing age with fertility requirements; 6. Patients allergic to the drugs involved in this study; 7. Patients deemed by researchers to be unsuitable for enrollment due to other factors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left Ventricular Ejection Fraction; | — |
Secondary
| Measure | Time frame |
|---|---|
| N-terminal pro-brain natriuretic peptide;Kansas City Cardiomyopathy Questionnaire;6-Minute Walk Distance; | — |
Countries
China
Contacts
Public ContactChen Yuewu
The Second Affiliated Hospital of Hainan Medical University
Outcome results
None listed